STANKOFF , Bruno

Multiple sclerosis (MS) is the most common demyelinating disease. In MS, demyelination occurs in the white matter of the brain and in the spinal cord. It is thus essential to measure the tissue myelin content to understand the physiopathology of MS, track progression and assess treatment efficacy. Positron emission tomography (PET) with...

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS). A reliable measure of the tissue myelin content is therefore essential to understand the physiopathology of MS, track progression and assess treatment efficacy. Positron emission tomography (PET) with [ 11 C]PIB has been proposed as a promising biomarker for...

Multiple sclerosis (MS) is a white matter (WM) disease characterized by the formation of WM lesions, which can be visualized by magnetic resonance imaging (MRI). The fluid-attenuated inversion recovery (FLAIR) MRI pulse sequence is used clinically and in research for the detection of WM lesions. However, in clinical settings, some MRI pulse...

Synopsis. Fluid-attenuated inversion recovery (FLAIR) MRI pulse sequence is used clinically and in research for the detection of WM lesions. However,in a clinical setting, some MRI pulse sequences can be missing because of patient or time constraints. We propose 3D fully convolutional neural networks to predict a FLAIR MRI pulse sequence from...

Detecting new lesions is a key aspect of the radiological follow-up of patients with Multiple Sclerosis (MS), leading to eventual changes in their therapeutics. Our pipeline for new lesion detection based on two consecutive FLAIR MRIs consists in two steps. We start by a detection of potential Region Of Interest (ROI) containing new lesions...

Multiple sclerosis (MS) is a demyelinating and inflammatory disease of the central nervous system (CNS). The de-myelination process can be repaired by the generation of a new sheath of myelin around the axon, a process termed remyelination. In MS patients, the demyelination-remyelination cycles are highly dynamic. Over the years, magnetic...

Detecting new lesions is a key aspect of the radiological follow-up of patients with Multiple Sclerosis (MS), leading to eventual changes in their therapeutics. This paper presents our contribution to the MSSEG-2 MICCAI 2021 challenge. The challenge is focused on the segmentation of new MS lesions using two consecutive Fluid Attenuated...

Multiple sclerosis (MS) is a demyenalinating inflammatory neurological disease. In vivo biomarkers of myelin content are of major importance for patient care and clinical trials. Positron Emission Tomography (PET) with Pittsburgh Compound B (PiB) provides a specific myelin marker. However, it is not available in clinical routine. In this paper,...

Background: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses. Objective: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV. Methods: Non-interventional observational retrospective, exposed/non-exposed cohort study nested...

Background: Choroid plexus (ChP) enlargement is an emerging radiological biomarker in multiple sclerosis (MS).Objectives: This study aims to assess ChP volume in a large cohort of patients with radiologically isolated syndrome (RIS) versus healthy controls (HC) and explore its relationship with other brain volumes, disease activity, and...

: MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing for MOG-antibodies is unavailable or shows uncertain results. We aimed to identify MRI and...

: Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all...

Background: Despite a second-line treatment with fingolimod (FNG), some patients with relapsing-remitting Multiple Sclerosis (RR-MS) may have residual disease activity. The current therapeutic strategy is based on the switch to either natalizumab (NTZ) or anti-CD20 (rituximab or ocrelizumab). To date the relative effectiveness of these two...